These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 10486787

  • 1. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
    Davies GC, Huster WJ, Shen W, Mitlak B, Plouffe L, Shah A, Cohen FJ.
    Menopause; 1999; 6(3):188-95. PubMed ID: 10486787
    [Abstract] [Full Text] [Related]

  • 2. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE, Bjarnason NH, Neven P, Plouffe L, Johnston CC, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [Abstract] [Full Text] [Related]

  • 3. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
    Mijatovic V, van der Mooren MJ, Kenemans P, de Valk-de Roo GW, Netelenbos C.
    Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
    [Abstract] [Full Text] [Related]

  • 4. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate.
    Neven P, Lunde T, Benedetti-Panici P, Tiitinen A, Marinescu B, de Villiers T, Hillard T, Cano A, Peer E, Quail D, Nickelsen T, Eurolox 1 Study Group.
    BJOG; 2003 Feb; 110(2):157-67. PubMed ID: 12618160
    [Abstract] [Full Text] [Related]

  • 5. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE, Botsis DS, Lambrinoudaki IV, Papagianni VD, Panoulis CP, Creatsa MG, Alexandrou AP, Augoulea AD, Dendrinos SG, Creatsas GC.
    Maturitas; 2006 Mar 20; 53(4):413-23. PubMed ID: 16140483
    [Abstract] [Full Text] [Related]

  • 6. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
    Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C.
    J Bone Miner Res; 1996 Jun 20; 11(6):835-42. PubMed ID: 8725181
    [Abstract] [Full Text] [Related]

  • 7. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
    Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C.
    N Engl J Med; 1997 Dec 04; 337(23):1641-7. PubMed ID: 9385122
    [Abstract] [Full Text] [Related]

  • 8. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Garrido L, Bosio-Le Goux B, Saráchaga M, Graebe A, Niño AJ, Nickelsen T.
    Am J Obstet Gynecol; 2004 Dec 04; 191(6):1979-88. PubMed ID: 15592280
    [Abstract] [Full Text] [Related]

  • 9. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
    Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, Young RL, Wells EC, O'Sullivan MJ, Chen B, Schenken R, Johnson SR, Women's Health Initiative Investigators.
    Obstet Gynecol; 2005 May 04; 105(5 Pt 1):1063-73. PubMed ID: 15863546
    [Abstract] [Full Text] [Related]

  • 10. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E, Malinen H, Sundström H, Penttinen J, Kauppila A.
    Acta Obstet Gynecol Scand; 1998 Aug 04; 77(7):758-63. PubMed ID: 9740525
    [Abstract] [Full Text] [Related]

  • 11. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
    Stovall DW, Utian WH, Gass ML, Qu Y, Muram D, Wong M, Plouffe L.
    Menopause; 2007 Aug 04; 14(3 Pt 1):510-7. PubMed ID: 17314736
    [Abstract] [Full Text] [Related]

  • 12. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study.
    Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Ehrlich K.
    Menopause; 2008 Aug 04; 15(1):51-8. PubMed ID: 18257142
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S, Walsh BW, Ciaccia AV, Siddhanti S, Rosen AS, Plouffe L.
    Obstet Gynecol; 2004 Feb 04; 103(2):267-73. PubMed ID: 14754694
    [Abstract] [Full Text] [Related]

  • 16. Effect of raloxifene on sexual function in postmenopausal women.
    Kessel B, Nachtigall L, Plouffe L, Siddhanti S, Rosen A, Parsons A.
    Climacteric; 2003 Sep 04; 6(3):248-56. PubMed ID: 14567773
    [Abstract] [Full Text] [Related]

  • 17. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
    Checa MA, Garrido A, Prat M, Conangla M, Rueda C, Carreras R.
    Maturitas; 2005 Sep 16; 52(1):70-7. PubMed ID: 16143228
    [Abstract] [Full Text] [Related]

  • 18. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.
    Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL.
    J Bone Miner Res; 1998 Nov 16; 13(11):1747-54. PubMed ID: 9797484
    [Abstract] [Full Text] [Related]

  • 19. Safety assessment of raloxifene over eight years in a clinical trial setting.
    Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL.
    Curr Med Res Opin; 2005 Sep 16; 21(9):1441-52. PubMed ID: 16197663
    [Abstract] [Full Text] [Related]

  • 20. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW, Bodmer C, Senn C, Fuchs G, Kraenzlin ME, Wyss H, Birkhaeuser MH, Lippuner K.
    Maturitas; 2006 Jan 20; 53(2):191-200. PubMed ID: 16368472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.